Date | Time | Room | Session Title | Presentation Time | Topic | Role |
---|---|---|---|---|---|---|
18/05/2023 | 08:10 to 10:15 | Di Cavalcanti |
Medical Medical Myeloid Neoplasms - Myelodysplastic Syndrome (MDS), Acute Myeloid Leukemia (AML) |
08:35 to 08:53 | What you need to know what has changed in classification in the MDS and AML: are blast counts becoming less relevant? | Speaker |
18/05/2023 | 08:10 to 10:15 | Di Cavalcanti |
Medical Medical Myeloid Neoplasms - Myelodysplastic Syndrome (MDS), Acute Myeloid Leukemia (AML) |
09:50 to 10:08 | The laboratory, molecular and genetic findings that influence my decisions in low-risk MDS: what can I not miss | Speaker |
18/05/2023 | 08:10 to 10:15 | Di Cavalcanti |
Medical Medical Myeloid Neoplasms - Myelodysplastic Syndrome (MDS), Acute Myeloid Leukemia (AML) |
08:53 to 09:00 | Q&A | Discussant |
18/05/2023 | 08:10 to 10:15 | Di Cavalcanti |
Medical Medical Myeloid Neoplasms - Myelodysplastic Syndrome (MDS), Acute Myeloid Leukemia (AML) |
10:08 to 10:15 | Q&A | Discussant |
18/05/2023 | 10:45 to 12:40 | Di Cavalcanti |
Medical Medical Myeloid Neoplasms - Myelodysplastic Syndrome (MDS), Acute Myeloid Leukemia (AML) |
11:10 to 11:28 | How do I prevent the progression of high-risk MDS to AML: who are the culprits, how do I treat today, and what “will tomorrow look like”? | Moderator |
18/05/2023 | 10:45 to 12:40 | Di Cavalcanti |
Medical Medical Myeloid Neoplasms - Myelodysplastic Syndrome (MDS), Acute Myeloid Leukemia (AML) |
11:28 to 11:35 | Q&A | Discussant |